Kuramochi-style 6-type Combined Immunotherapy: Comprehensive Reconstruction of the Immune Defense Line

Developed by Dr. Tsuneo Kuramochi (deceased) in Japan, the "6-type Combined Immunotherapy" is a next-generation cellular therapy. Unlike traditional treatments that target only a single cell type (such as NK cells alone or dendritic cells alone), this technology simultaneously activates and massively proliferates six key types of immune effector cells within the human body.

Core Technology: Synergistic Action of Six Cell Types

Under strictly controlled laboratory conditions, this therapy expands the following cells from tens of millions to 2 to 5 billion cells:

1. γδ T cells: Possess powerful innate anti-cancer capabilities.
2. NK cells (Natural Killer cells): Instantly detect and eliminate mutated cells.
3. NKT cells: Combine characteristics of both T and NK cells; they are resilient to chemotherapy and radiotherapy.
4. Cytotoxic T Lymphocytes (CTL): Execute precision strikes after receiving cues from dendritic cells.
5. Dendritic Cells (DC): The commanders of the immune system, receiving WT1 antigen prompts to precisely identify cancer cells.
6. Helper T cells: Secret cytokines to regulate and strengthen the overall immune response.

Why Choose 6-type Combined Immunotherapy?

• Patented Protection: This simultaneous activation technology is patented in Japan and South Korea, ensuring its scientific rigor.
• Broad Applicability: Applicable to almost all solid tumors, with the exception of certain leukemias and malignant lymphomas.
• Minimal Side Effects: Since the treatment utilizes the patient's own cells for proliferation, the physical burden is minimal, and hospitalization is not required.
• Synergistic Effects: NKT cells are highly resilient to anti-cancer drugs, making this therapy suitable for use alongside standard chemotherapy and radiotherapy to help alleviate side effects and improve quality of life.
• Recurrence Prevention: It is also used post-surgery to eliminate residual cancer cells and reduce the risk of metastasis.

Treatment Process

The treatment typically involves blood collection followed by intravenous infusion. The cell culture cycle takes approximately three weeks. As an outpatient treatment, patients can maintain their normal daily routines without altering their social or professional schedules.

About Senshin (Advanced) Clinic

This therapy is administered at "Senshin Clinics" located in cities such as Fukuoka and Tokyo. Led by current director Dr. Toshihide Aso, the medical team leverages extensive clinical data to help numerous mid-to-late-stage cancer patients regain hope in their fight against the disease.

[Medical Supporter Compliance Statement] Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).